Overall survival in cancer drug trials as a new surrogate end point for overall survival in the real world

JAMA Oncology

Volumn 3, Issue 7, 2017, Pages 889-890

  Mailankody, Sham ^a   Prasad, Vinay ^b  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; SORAFENIB; BIOLOGICAL MARKER;

ADVANCED CANCER; AGE DISTRIBUTION; CANCER SURVIVAL; CHARLSON COMORBIDITY INDEX; CHILD PUGH SCORE; DISEASE SURVEILLANCE; DRUG EFFICACY; DRUG SAFETY; FOOD AND DRUG ADMINISTRATION; HUMAN; LIVER CELL CARCINOMA; MEDICARE; OVERALL SURVIVAL; PROPENSITY SCORE; SHORT SURVEY; SOLID MALIGNANT NEOPLASM; CLINICAL TRIAL (TOPIC); DISEASE FREE SURVIVAL; DRUG APPROVAL; LEGISLATION AND JURISPRUDENCE; MORTALITY; NEOPLASM; ORGANIZATION AND MANAGEMENT; SAMPLE SIZE; SURVIVAL ANALYSIS; UNITED STATES;

ANTINEOPLASTIC AGENTS; BIOMARKERS; CLINICAL TRIALS AS TOPIC; DISEASE-FREE SURVIVAL; DRUG APPROVAL; HUMANS; NEOPLASMS; SAMPLE SIZE; SURVIVAL ANALYSIS; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 85024887969     PISSN: 23742437     EISSN: 23742445     Source Type: Journal    
DOI: 10.1001/jamaoncol.2016.5296     Document Type: Short Survey

References (8)

1. Kim C, Prasad V. Strength of validation for surrogate end points used in the US Food and Drug Administration’s approval of oncology drugs [published online May 10, 2016]. Mayo Clin Proc. doi:10.1016/j.mayocp.2016.02.012
2. Fojo T, Mailankody S, Lo A. Unintended consequences of expensive cancer therapeutics—the pursuit of marginal indications and a me-too mentality that stifles innovation and creativity: the John Conley Lecture. JAMA Otolaryngol Head Neck Surg. 2014;140(12):1225-1236.
3. Kumar H, Fojo T, Mailankody S. An appraisal of clinically meaningful outcomes guidelines for oncology clinical trials. JAMA Oncol. 2016;2(9): 1238-1240.
4. Scher KS, Hurria A. Under-representation of older adults in cancer registration trials: known problem, little progress. J Clin Oncol. 2012;30(17): 2036-2038.
5. Singh H, Kim G, Maher VE, et al. FDA subset analysis of the safety of nivolumab in elderly patients with advanced cancers. J Clin Oncol (Meeting Abstracts). 2016;34(15 suppl):10010.
6. Prasad V, Massey PR, Fojo T. Oral anticancer drugs: how limited dosing options and dose reductions may affect outcomes in comparative trials and efficacy in patients. J Clin Oncol. 2014;32 (15):1620-1629.
7. Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008;359(4):378-390.
8. Sanoff HK, Chang Y, Lund JL, O’Neil BH, Dusetzina SB. Sorafenib effectiveness in advanced hepatocellular carcinoma. Oncologist. 2016;21(9): 1113-1120.